Skip to main content

Search

Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure. A Randomised Double-blind Placebo-controlled International Multicenter Study. Servier Terminated Ivabradine 3 CL3-16257-083 KFMC
Effects of Add on Pegylated Interferon therapy in patients of Chronic hepatitis B in maintained response with ongoing nucleos(t)ide analogues ; A multicenter, prospective, randomized open label trial. KAIMRC Ongoing PEGINTERFERON ALFA-2A, RO258310 RIBAVIRIN, R0209963 3 RC14-055-R NGHA-R
Effect of subcutaneous semaglutide 2.4 mg once-weekly compared to placebo in subjects with obesity and knee osteoarthritis Novo Nordisk Ongoing semaglutide 3 NN9536-4578 King Fahad Medical City (Riyadh)
Effect of Preoperative Administration of Ibuprofen in Children Undergoing Extraction for Reducing Postoperative Pain: A Double-blind Randomized Controlled Clinical Trial Princess Nourah University Completed ibuprofen 3 18-0253 PNU-CD
Effect of Gum Arabic supplementation on butyrate, uremic retention molecules and inflammation in chronic kidney disease patients King Fahad Specialist Hospital - Dammam / KACST Completed Gum Arabic / E-114 2 2 KFSH
Early administration of Tocilizumab in Immunocompromised and potential high-risk patients for developing COVID-19 King Faisal Specialist Hospital & Research Centre Completed TOCILIZUMAB 2 2201070 KFSH&RC-R
Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG) KKUH Ongoing Heparin - Enoxaparin - Tinzaparin - Fondaparinux 3 1.2 King Khalid University Hospital (Riyadh)
"Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic ( RAPID COVID COAG) " KAIMRC Completed TINZAPARIN SODIUM 3 RC20/403 King Abdulaziz Medical City NG (Riyadh)
Circulating Endotoxin as a Contributing Inflammatory Mediator in Osteoporosis Risk and its Association with Vitamin D Deficiency National Plan for Science and Technology Ongoing Vitamin D3 VS. Alendronate 3 11-MED-2113-02 or (G1109-665) KFMC
Cholecalciferol supplementation in critically ill patients with severe vitamin D deficiency in intensive care unit – a randomized controlled trial King Abdullah Medical City, Makkah Ongoing VITAMIN D3 (CHOLECALCIFEROL) 3 IRB#16-252, V2 KAMC
View 341 - 350 From 828